scholarly journals Atopic dermatitis in adolescents and adults – the evaluation of association with other allergic diseases and parameters

2017 ◽  
Vol 28 (6) ◽  
pp. 933-948 ◽  
Author(s):  
Jarmila Celakovska ◽  
Josef Bukač ◽  
Karel Ettler ◽  
Květuše Ettlerova ◽  
Irena Krcmova
Keyword(s):  
Atopic Dermatitis ◽  
Allergic Diseases ◽  
Adolescents And Adults

scholarly journals The increased prevalence of keloids in atopic dermatitis patients with allergic comorbidities: a nationwide retrospective cohort study

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hyo-Eun Kwon ◽  
Hye-Jin Ahn ◽  
Su Jin Jeong ◽  
Min Kyung Shin
Keyword(s):  
Atopic Dermatitis ◽  
Medical Records ◽  
Dermal Fibroblast ◽  
Allergic Diseases ◽  
Control Group ◽  
T Helper ◽  
Logistic Regression Models ◽  
Adolescents And Adults ◽  
Allergic Contact ◽  
Information Database

AbstractAtopic dermatitis (AD) is associated with allergic comorbidities, such as asthma, allergic rhinitis (AR), and allergic contact dermatitis (ACD). The etiology of keloid is largely unknown; however, AD and keloid share inflammatory pathways characterized by T-helper cell 2 cytokines and increased dermal fibroblast activity. The prevalence of keloids has been reported to increase in patients with AD, but it remains controversial. This study aimed to estimate the prevalence of keloids in patients with AD, and compare it with the prevalence of other comorbidities of AD. We assessed the Korean National Health Information Database and medical records including coexisting asthma, AR, and ACD. Single and multiple logistic regression models were created for keloids and each allergic disease. The prevalence of keloids was higher in the AD group than in the control group. Among patients with AD, adolescents and adults had a higher prevalence of keloids than infants and children. The risk of keloids was high with AD alone, and coexisting asthma significantly increased the risk. Similarly, the risk of keloids was higher in AR associated with AD and ACD associated with AD than in AD alone. Thus, among Koreans, patients with AD have a higher risk of keloid development, with coexisting allergic diseases increasing the risk.

scholarly journals Big Data Research on Keloids in Atopic Dermatitis Patients with Allergic Comorbidities: Increased Prevalence of Keloids in Atopic Dermatitis

2021 ◽  
Author(s):  
Hyo-eun Kwon ◽  
Hye-Jin Ahn ◽  
Su Jin Jeong ◽  
Min Kyung Shin
Keyword(s):  
Atopic Dermatitis ◽  
Medical Records ◽  
Dermal Fibroblast ◽  
Allergic Diseases ◽  
Control Group ◽  
T Helper ◽  
Logistic Regression Models ◽  
Adolescents And Adults ◽  
Allergic Contact ◽  
Information Database

Abstract Atopic dermatitis (AD) is associated with allergic comorbidities, such as asthma, allergic rhinitis (AR), and allergic contact dermatitis (ACD). The etiology of keloid is largely unknown; however, AD and keloid share inflammatory pathways characterized by T-helper cell 2 cytokines and increased dermal fibroblast activity. The prevalence of keloids is known to increase in patients with AD. This study aimed to estimate the prevalence of keloids in patients with AD, and compare it with the prevalence of other comorbidities of AD. We assessed the Korean National Health Information Database and medical records including coexisting asthma, AR, and ACD. Single and multiple logistic regression models were created for keloids and each allergic disease. The prevalence of keloids was higher in the AD group than in the control group. Among patients with AD, adolescents and adults had a higher prevalence of keloids than infants and children. The risk of keloids was high with AD alone, and coexisting asthma significantly increased the risk. Similarly, the risk of keloids was higher in AR associated with AD and ACD associated with AD than in AD alone. Thus, among Koreans, patients with AD have a higher risk of keloid development, with coexisting allergic diseases increasing the risk.

scholarly journals 417 The molecular features of normal and atopic dermatitis skin in infants, children, adolescents and adults

2021 ◽  
Vol 141 (5) ◽  
pp. S72
Author(s):  
Y. Renert-Yuval ◽  
E. Del Duca ◽  
A.B. Pavel ◽  
M. Fang ◽  
R.L. Lefferdink ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Molecular Features ◽  
Adolescents And Adults

scholarly journals Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD

2020 ◽  
Author(s):  
Rebecca Hall ◽  
Mark G. Lebwohl ◽  
Andrew G. Bushmakin ◽  
Eric L. Simpson ◽  
Melinda J. Gooderham ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Content Validation ◽  
Adolescents And Adults

scholarly journals APPLICATION OF VITAMIN D IN DIFFERENT DOSAGE TO TREAT CHILDREN WITH ALLERGIC DISEASES

2020 ◽  
Vol 73 (7) ◽  
pp. 1377-1383
Author(s):  
Olexandra V. Tiazhka ◽  
Zoriana V. Selska
Keyword(s):  
Allergic Rhinitis ◽  
Atopic Dermatitis ◽  
Blood Serum ◽  
Bronchial Asthma ◽  
Vitamin D3 ◽  
Allergic Diseases ◽  
Acute Disease ◽  
Disease Remission ◽  
Significant Difference ◽  
Different Doses

The aim: To study the dynamics of the level of 25(ОН)D, ІL-4, ІL-10, and IgG in the blood serum of children with allergic diseases and to study the clinical effect of vitamin D3 administration n different dosage in this category of patients. Materials and methods: 153 children aged 3-16 with such allergic diseases as bronchial asthma, atopic dermatitis and allergic rhinitis have been examined. The level of 25(ОН) D was determined using the electrochemiluminescence method, while the levels of ІL-4, ІL-10 and IgG were assessed using enzyme-linked immunoassay. Results: In the contrasting of the initial level of 25(ОН)D in the blood serum of patients after administration of 2,000 IU of vitamin D3 over 2 months, after summer and after treatment with cholecalciferol in higher doses (4,000–5,000 IU) over 2 months, significant difference was established between the indicators by the Friedman criterion (λ2 = 41.211; P < 0.05). In the similar contrasting of ІL-4 indicators, a significant difference between them was traced (P < 0.05) in the period of acute disease as well as the downward tendency in the period of remission. In the similar contrasting of ІL-10 indicators, a significant difference between them was traced (P < 0.05) in the acute period and in the period of disease remission. In the similar contrasting of IgG indicators, a downward tendency was traced in the period of acute disease and significant decrease (P < 0.05) – in the period of disease remission. In the contrasting of 25(ОН)D and ІL-4, ІL-10 figures a strong reverse correlation relationship was traced. The therapeutic effect of the administration of vitamin D3 medication in different doses in children with allergic diseases was traced. Conclusions: The data obtained shows that in the treatment of children with bronchial asthma, allergic rhinitis and atopic dermatitis the complex therapy should include vitamin D3 medications in different doses within a long-term course of treatment.

scholarly journals Prevention of Transcutaneous Sensitization to Cow Milk Proteins in Infants with Atopic Dermatitis: Cohort Study

2020 ◽  
Vol 19 (6) ◽  
pp. 538-544
Author(s):  
Nikolay N. Murashkin ◽  
Svetlana G. Makarova ◽  
Stepan G. Grigorev ◽  
Dmitri V. Fedorov ◽  
Roman A. Ivanov ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
Maintenance Therapy ◽  
Milk Proteins ◽  
Allergic Diseases ◽  
Specific Ige ◽  
Dispersion Analysis ◽  
Cow Milk ◽  
Group 2 ◽  
Group 1

Background. Malformations in epidermal barrier in children with atopic dermatitis (AD) can cause transcutaneous sensitization with further development of allergic diseases that can worsen the AD course and significantly reduces patients’ quality of life.Objective. The aim of the study was to determine the effect of topical treatment and maintenance therapy with pimecrolimus 1% cream (PIM) and topical glucocorticosteroids (tGCS) in infants with AD on reducing the risk of developing transcutaneous sensitization (due to the levels of specific IgE to the cow milk protein over time) and on reducing the disease severity (by the EASI scale).Methods. The study included children aged from 1 to 4 months with early manifestations of moderate and severe AD. The severity of AD was estimated via the EASI scale at start of observation, then at 6, 9 and 12 months of life. The class and level of specific IgE to cow milk proteins (CMP) were determined by the ImmunoCAP method at the point of enrolment and at the ages of 6 and 12 months. Statistical analysis of studied indicators dynamics and their comparison in research groups was carried out using multifactorial dispersion analysis.Results. The study included 36 patients. All patients have received standard tGCS therapy in combination with emollients (wet wrap) for 10 days. The maintenance therapy was prescribed in postacute period. It included topical calcineurin inhibitor PIM 2 times/day for 3 months, then double application (morning/evening) 3 times/week up to the age of 1 year old (group 1). Other group had maintenance therapy — tGCS2 times/week for 3 months, and then at AD aggravation (group 2). Group 1 has shown lower level of sensitization to CMP at the age of 6 and 12 months and more significant decrease in AD severity according to EASI scale compared to group 2.Conclusion. The treatment with PIM is effective in therapy of AD and prevention of transcutaneous sensitization in infants.

Sign in / Sign up

Export Citation Format

Share Document